Anixa Biosciences Inc (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, announced on Tuesday that it has administered the second dose of its chimeric antigen receptor T-cell (CAR-T) therapy to an individual patient.
This move follows a positive response after the initial treatment in the ongoing Phase 1 clinical trial of its CAR-T therapy for ovarian cancer. The study is being carried out in partnership with Moffitt Cancer Center.
Anixa and Moffitt previously received approval for a single-patient IND application, allowing the administration of a second dose to a patient whose tumour biopsy revealed cellular infiltration and necrosis, indicating biological activity of the CAR-T therapy.
After the first infusion, the subject remained stable and did not need alternative treatment and her quality of life was good, resulting in the decision to administer a second dose to further improve these positive results. These findings provide promising indications that the CAR-T therapy could serve as a successful long-term treatment option.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Anixa Biosciences administers second dose of CAR-T therapy to individual patient
RevOpsis Therapeutics receives SBIR grant of over USD1.8m
AtomVie Global Radiopharma partners with Radiopharm Ventures
Lipella granted patent for innovative drug delivery technology
Adocia patents stable hormone combinations for obesity and diabetes
Accord BioPharma's IMULDOSA receives US FDA approval to treat chronic inflammatory conditions
RedHill Biopharma's opaganib selected for Ebola treatment development by BARDA
Quest Diagnostics acquires OhioHealth lab assets
Exelixis and Merck collaborate on clinical development of zanzalintinib
BD launches automated reagent kit to streamline single-cell discovery studies
Transgene's Phase II trial of TG4001 falls short of primary objective
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
SkylineDx reveals new data from the MERLIN_001 prospective US multi-centre trial